- Home
- NDMO vs ARCT Comparison
NDMO vs ARCT Comparison
Compare NDMO & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NDMO | ARCT |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 626.1M | 206.0M |
| IPO Year | 2019 | 2019 |
Fundamental Metrics
Financial Performance| Metric | NDMO | ARCT |
|---|---|---|
| Price | $10.18 | $6.66 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $28.33 |
| AVG Volume (30 Days) | 111.0K | ★ 413.9K |
| Earning Date | 01-01-0001 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $82,031,000.00 |
| Revenue This Year | N/A | $0.34 |
| Revenue Next Year | N/A | $93.19 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.30 | $5.85 |
| 52 Week High | $10.82 | $24.14 |
Technical Indicators
Market Signals| Indicator | NDMO | ARCT |
|---|---|---|
| Relative Strength Index (RSI) | 27.69 | 36.96 |
| Support Level | $9.94 | $5.93 |
| Resistance Level | $10.32 | $7.88 |
| Average True Range (ATR) | 0.11 | 0.47 |
| MACD | -0.05 | -0.13 |
| Stochastic Oscillator | 8.77 | 1.99 |
Price Performance
Historical ComparisonAbout NDMO Nuveen Dynamic Municipal Opportunities Fund of Beneficial Interest
Nuveen Dynamic Municipal Opportunities is a closed-end management investment company. Its investment objective is to seek total return through income exempt from regular federal income taxes and capital appreciation. A majority of its investments are made in municipal securities, the income from which is exempted from regular federal income taxes.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.